116 search results for: symposium
UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.
UEGW 2024 | WHY Is Long-Term Management of EoE Important?
Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.
UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.
Bullous Pemphigoid (BP): Exploring New Frontiers
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Join Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau as they discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, treatment challenges, and emerging therapies.
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?
Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
ADVENT at UEG Week 2026
Sit down with three leading experts—Professors David Rubin, MD; Evan Dellon, MD; and Thomas Greuter, MD—for a patient case–based roundtable titled "Are We Ready to Treat to Target in EoE? Applying the IBD Paradigm to Emerging Evidence in EoE Management." The discussion will bring together inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) perspectives on progression and esophageal remodeling in EoE.
